ArticleClinical and translational medicine2020

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.

Zhonghan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.